Novo Nordisk invests DKK 8.5bn into new Danish modular production site

Published: 16-Dec-2024

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Novo Nordisk is planning to invest DKK 8.5bn into the construction of a new pharmaceutical production facility in Odense, Denmark. 

The site, which spans across more than 40,000m2, will include both finished production capabilities and warehouse space.

Designed to be both modular and flexible, the facility will be equipped to produce a range of product types within the rare disease category — including haemophilia.

Novo Nordisk has also vouched to preserve the biodiversity of the area by planting trees at ther site, while also installing solar panels on the site's roof to boost onsite electricity generation. 

To further support the local wildlife, Novo Nordisk will reuse excess soil, wood materials and other resources to create lakes, forests and community spaces for the local people. 

Construction is currently underway, and will likely be completed by 2027.

Once inaugurated, the Odense facility will create 400 new permanent roles.

Executive VP of Product Supply, Quality & IT at Novo Nordisk, Henrik Wulff, commented: "The facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand for our life-changing medicines,” 

“We are proud to build on our heritage in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and talented workforce."

 

 

You may also like